Glycomic mapping of pseudomucinous human ovarian cyst glycoproteins: identification of Lewis and sialyl Lewis glycotopes

Expression of sialyl Lewis x (sLe(x)) and sialyl Lewis a (sLe(a)) on cell-surface glycoproteins endows cells with the ability to adhere to E-, P-, and L-selectins present on endothelia, platelets, or leukocytes. Special arrangements of these glycotopes in cancers are thought to play a key role in metastasis. Previous studies have mostly described membrane-bound sLe(x) and sLe(a) activities. In this report, the major O-glycans of the secreted human ovarian cyst sialoglycoproteins from a Le(a+) nonsecretor individual (human ovarian cyst sample 350) were characterized by MS/MS analyses and immuno-/lectin-chemical assays. The results showed that HOC 350 carries a large number of epitopes for sLe(x), sLe(a), and Le(a) reactive antibodies. Advanced MS/MS sequencing coupled with mild periodate oxidation and exoglycosidase digestions further revealed that the O-glycans from HOC 350 are mostly of core 1 and 2 structures, extended and branched on the 3-arm with both type I and type II chains, complete with variable degrees of terminal sialylation and/or fucosylation to yield the sLe(x) or sLe(a) epitopes. Thus, the underlying core and peripheral backbone structures are similar to that of a previously proposed composite structural model for nonsialylated human ovarian cysts O-glycans, but with some notable distinguishing structural features in addition to sialylation.     

Identification of blood group A/A‐Leb/y and B/B‐Leb/y active glycotopes co‐expressed on the O‐glycans isolated from two distinct human ovarian cyst fluids

Although the individual human blood group A and B determinants are well defined, their co‐expression pattern on a particular glycan carrier in individuals of blood group AB status has not been delineated. To address this issue, complex O‐glycans were isolated from two distinct sources of human ovarian cyst glycoproteins (HOC 89 and Cyst 19) and profiled by advanced MS analyses, in conjunction with defining their binding characteristics against a panel of lectins and monoclonal antibodies. The major O‐glycans of HOC 89 were found to correspond to sialyl Tn, mono‐ and di‐sialyl T structures, whereas those of Cyst 19 were apparently more heterogeneous and extended to larger sizes. A minimal structure that carries both A and B determinants on the same molecule was identified, in which the A epitope is attached directly to the core GalNAc, whereas the B epitope is preferentially located on the six arms of a core 2 structure. Both arms can be further extended with internal fucosylation that appears to be restricted to those non‐sialylated chains already carrying the terminal ABH determinants, thus giving rise to rather prominent A/B‐Le^b/y glycotopes on larger O‐glycans.     

New applications of ruthenium solar cell sensitizers N3 and N719 as luminescence turn-on anion sensors

Optical sensing of F⁻, Cl⁻, Br⁻, I⁻, OAc⁻, , , and by cis-dithiocyanatobis(2,2′-bipyridyl-4,4′-dicarboxylic acid)ruthenium(II) (N3) and bis(tetrabutylammonium) cis-dithiocyanatobis(2,2′-bipyridine-4-COOH,4′-COO⁻)ruthenium(II) (N719) have been investigated in dimethyl sulfoxide (DMSO), by means of UV-Vis absorption and emission spectrophotometric titrations. Additions of F⁻, OAc⁻, and in DMSO solution caused obvious UV-Vis spectral changes with appearance of several isosbestic points, and remarkable emission enhancements along with large blue shifts in emission bands. The values of F⁻-induced emission intensity enhancement factor (emission quantum yield enhancement factor), I/I₀ (φ/φ₀), were found to be 40 (86) and 38 (58) for N3 and N719, respectively. No obvious spectral changes were observed upon addition of Cl⁻, Br⁻, I⁻, and in DMSO solutions. Luminescent F⁻ sensing in DMSO/H₂O (4:1, v/v) has also been demonstrated to be operative with a luminescence enhancement factor of 12, indicating that N3 is very potential for practical application as fluorescent anion sensor in aqueous solution. An interaction mechanism of anion-induced deprotonation of N3 and N719 was confirmed, and the deprotonation reaction equilibrium constants of N3 and N719 were derived as well.     

Structure of the Catalytic aa Fragment of the Protein Disulfide Isomerase ERp72

Protein disulfide isomerases (PDIs) are responsible for catalyzing the proper oxidation and isomerization of disulfide bonds of newly synthesized proteins in the endoplasmic reticulum (ER). The ER contains many different PDI-like proteins. Some, such as PDI, are general enzymes that directly recognize misfolded proteins while others, such as ERp57 and ERp72, have more specialized roles. Here, we report the high-resolution X-ray crystal structure of the N-terminal portion of ERp72 (also known as CaBP2 or PDI A4), which contains two a⁰a catalytic thioredoxin-like domains. The structure shows that the a⁰ domain contains an additional N-terminal β-strand and a different conformation of the β5-α4 loop relative to other thioredoxin-like domains. The structure of the a domain reveals that a conserved arginine residue inserts into the hydrophobic core and makes a salt bridge with a conserved glutamate residue in the vicinity of the catalytic site. A structural model of full-length ERp72 shows that all three catalytic sites roughly face each other and positions the adjacent hydrophobic patches that are likely involved in protein substrate binding.     

Leishmanicidal effect of LLD-3 (1), a nor-triterpene isolated from Lophanthera lactescens

Leishmanicidal activity of 6α, 7α, 15β, 16β, 24-pentacetoxy-22α-carbometoxy-21β,22β-epoxy-18β−hydroxy-27,30-bisnor-3,4-secofriedela-1,20 (29)-dien-3,4 R-olide (LLD-3 (1)) isolated from Lophanthera lactescens Ducke, a member of the Malpighiaceae, was demonstrated against intramacrophage amastigote forms (IC₅₀ of 0.41 μg/mL). The in vitro leishmanicidal effect of Glucantime, the first choice drug for leishmaniasis treatment, was increased by LLD-3 (1) association. The leishmanicidal effect of LLD-3 (1) was not due to stimulation of nitric oxide production by macrophages. LLD-3 (1) was also not cytotoxic for mouse peritoneal macrophages or B cells as assessed by the XTT and Trypan blue exclusion assays. LLD-3 (1) was unable to affect proliferation of naïve or activated B and T cells, as well as the B cells immunoglobulin synthesis. Cellularity of different tissues, liver and kidney functions were not altered in mice treated with LLD-3 (1), as well as the histology pattern of different organs. Our results add LLD-3 (1) as a potential drug candidate for treatment of leishmaniasis.